Bristol-Myers SquibbBMY
BMY
About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees: 34,100
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 315 | Existing positions closed: 105
50% more funds holding in top 10
Funds holding in top 10: 26 [Q3] → 39 (+13) [Q4]
11% more capital invested
Capital invested by funds: $82.1B [Q3] → $91.1B (+$8.98B) [Q4]
5% more funds holding
Funds holding: 2,221 [Q3] → 2,326 (+105) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 886 | Existing positions reduced: 870
0% more call options, than puts
Call options by funds: $1.75B | Put options by funds: $1.75B
0.25% less ownership
Funds ownership: 78.38% [Q3] → 78.14% (-0.25%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
1%
downside
Avg. target
$63
13%
upside
High target
$70
25%
upside
6 analyst ratings
2 positive
33%
4 neutral
67%
0 negative
0%
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target | 11%upside $62 | Equal-Weight Maintained | 7 Feb 2025 |
Cantor Fitzgerald Olivia Brayer 39% 1-year accuracy 9 / 23 met price target | 1%downside $55 | Neutral Maintained | 4 Feb 2025 |
Citigroup Andrew Baum 50% 1-year accuracy 3 / 6 met price target | 16%upside $65 | Neutral Maintained | 28 Jan 2025 |
Truist Securities Robyn Karnauskas 27% 1-year accuracy 6 / 22 met price target | 16%upside $65 | Buy Maintained | 8 Jan 2025 |
Jefferies Akash Tewari 25% 1-year accuracy 3 / 12 met price target | 25%upside $70 | Buy Upgraded | 16 Dec 2024 |
Financial journalist opinion
Based on 46 articles about BMY published over the past 30 days
Positive
Seeking Alpha
16 hours ago
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is Breyanzi, whose sales amounted to $263 million in the fourth quarter of 2024, an increase of 160.4% year-on-year. On the other hand, Camzyos is gradually becoming the flagship of Bristol-Myers Squibb's cardiovascular franchise.
Neutral
PRNewsWire
2 days ago
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.
Positive
Benzinga
2 days ago
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Neutral
Business Wire
3 days ago
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant.
Positive
Seeking Alpha
5 days ago
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” - Barron's Weekly. In a Barron's interview, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.
Neutral
Business Wire
6 days ago
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis.
Neutral
Business Wire
1 week ago
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial.
Negative
Zacks Investment Research
1 week ago
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
Neutral
Benzinga
1 week ago
What's Going On With Bristol Myers Squibb Stock On Monday?
Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Positive
Zacks Investment Research
1 week ago
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Charts implemented using Lightweight Charts™